GSK 215 is a potent and selective focal adhesion kinase (FAK) Degrader (PROTAC™; pDC50 = 8.4, last for 96 h). Comprises the FAK inhibitor, PND 1186 (Cat. No. 6891), joined by a linker to a VHL E3 ligase ligand. Kinome binding (KinoBead profiling) shows GSK 215 (at 10 nM) has high selectivity for the FAK kinase domain. GSK 215 inhibits cell proliferation in MCF-7 and A549 cells and suppresses A549 cell motility in a wound scratch model system. In CD1 mice, GSK 215 injection induces rapid and profound degradation of FAK in liver (Dmax = 85% at 18h).
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-151103 |
|---|
| Réf. fabricant | 18706285 |
|---|
| Nom chimique ou matériau | (2 S,4 R)-4-Hydroxy-1-(-2-(2-(4-(3-methoxy-4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)piperazin-1-yl)acetamido)-3,3-dimethylbutanoyl)-N-(-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
|---|
| CAS | 2743427-26-9 |
|---|
| Quantité | 5 mg |
|---|
| Cible | Active Degraders |
|---|
| Formule moléculaire | C<sub>50</sub>H<sub>59</sub>F<sub>3</sub>N<sub>10</sub>O<sub>6</sub>S |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
